Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-y PET Imaging: Bench to Bedside
NCT06439914Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [89Zr]Zr-DFO-emapalumab in non-small cell lung cancer (NSCLC). Primary endpoints: peak Standard Uptake Value at Day 45, mean Standard Uptake Value at Day 45 and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
[89Zr]Zr-DFO-emapalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06439914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439914.